Corcept Therapeutics Incorporated (CORT) Stock: Price, Forecast & Analyst Target
Corcept Therapeutics Incorporated (CORT) — MoonshotScore 91/100 (Exceptional band), calculated Oct 4, 2026. Price $116.23 (+1.93%), as of the Oct 2, 2026 trading session; market cap $12.6B. Expected results Nov 4, 2026.
Educational signal · not a buy or sell recommendation · How to read this
Market value / cash and short-term investments: 40.88× (market value Oct 2, 2026; cash Jun 30, 2026) · expected results Nov 4, 2026
Corcept Therapeutics Incorporated · CORT · NASDAQ · Healthcare · Medical - Pharmaceuticals
Research dated 2026-09-13: Corcept Therapeutics sells Korlym for hypercortisolism in adults with Cushing’s syndrome while developing selective cortisol modulators for endocrine and oncology uses. The equity story depends on whether Korlym can sustain expanding commercial spending and pipeline investment until relacorilant becomes a meaningful complement, while a demanding valuation already anticipates substantial growth.
Price as of Oct 2, 2026
Key Statistics
MoonshotScore v2 · Corcept Therapeutics (CORT)
ExceptionalWhy this rating? Method, drivers & history
Bands for the MoonshotScore: Exceptional 80-100 · Strong 65-79 · Fair 45-64 · Weak below 45.
- Business Quality — Is this a genuinely good business?
- Financial Safety — Could this blow up on me?
- Valuation — Am I paying a fair price?
- Growth Durability — Is the growth real and likely to last?
- Momentum — Is the market already moving on this?
Elite quality and a fortress balance sheet, but weak growth and a full valuation; the market is already moving on it. Business Quality: Elite; Financial Safety: Fortress; Valuation: Rich; Growth Durability: Fading; Momentum: Surging.
Enterprise value relative to EBITDA is the main valuation drag relative to sector peers.
- quarterly revenue $256M (Q2 FY2026, quarter ended Jun 2026)
- EPS beat 3 of 8
- Altman Z 43.66 · Piotroski F 6
Holding back: a rich price
Helping: business quality, balance-sheet strength, positive momentum
What has the MoonshotScore done over time?
| Recorded | Score | Band |
|---|---|---|
| 91 | Exceptional | |
| 91 | Exceptional | |
| 91 | Exceptional | |
| 91 | Exceptional | |
| 91 | Exceptional | |
| 91 | Exceptional |
The score was 91 in the stored Oct 3, 2026 snapshot and remains 91 in the current publication computed Oct 4, 2026 (0).
Calculation uses the most recent completed US trading session. Live price changes do not update the score immediately.
Computed · Educational signal · not a buy or sell recommendation · How the MoonshotScore is computed →
Price & valuation
| Measure | Value |
|---|---|
| Latest provided price | $116.23 |
| Change on the day | +1.93% |
| 52-week range | $28.66–$126.38 |
| Market capitalisation | $12.6B |
| Price / earnings (trailing) | 223.52 |
| Shares traded on the day | 930.2K |
| Beta (volatility vs the S&P 500) | 0.45 |
Price & events
Triangles mark reported quarters on the line: pointing up is above the recorded estimate, down is below, a diamond means no estimate on file or a dated event that is not a results report. Numbers key to the dated list. Point at or tab to any week for its close.
Events behind the price
- · Earnings results · below the recorded estimate
- · Earnings results · below the recorded estimate
- · Earnings results · below the recorded estimate
- · Earnings call · management outlook
- · Earnings results · above the recorded estimate
Results dates follow the earnings feed; call dates follow the transcript provider. Nearby dates do not establish that an event caused a price move.
Upcoming events
Management outlook
We expect growth to continue and have increased our 2026 revenue guidance to a range of $1.1 billion to $1.2 billion Net income was $43 million in the second quarter of 26, compared to net income of $35 million in the prior year period.
Atabak Mokari · Statement from
Statement dates identify the earnings call, not a deadline. Management expectations and provider estimates can change.
Read management statementsCouncil Score · weighted blend of 2 available disciplines
Council score for Corcept Therapeutics (CORT): Strongly Bullish
80/100 · A+Council is a separate blend of available disciplines; MoonshotScore above remains the five-pillar research rating.
5-Factor Breakdown
Legends Council
6 lenses, 6 current
AI simulations built from the named investors' published principles. Not affiliated with, endorsed by, or the opinion of these individuals. How these lenses are built
Read on: Oct 4, 2026
Munger's Mindset
Balance Sheet & Valuation · historical
Read on: Sep 9, 2026 · older than the 27 hours refresh window; not a current reading
How to read these bars and different assessments
Council is a separate blend of available disciplines; MoonshotScore above remains the five-pillar research rating.
Bars show each model's ordered assessment on its own scale, not a probability or a comparable investment return. The adjacent words give the assessment; more filled segments indicate a stronger model reading.
On Sep 9, 2026, the Munger lens read the price at that time as overvalued against its own estimate of value.
Readings on this page are from Oct 5, 2026, except a card that shows its own read date.
Watch the CORT film — every key number, told as a short cinematic story
~2 min · open the film
What is Corcept Therapeutics (CORT), and what does it report?
Short answer · as of
Corcept is a commercial pharmaceutical company built around cortisol modulation, not a development-stage biotechnology company waiting for initial product revenue. Korlym is its primary marketed treatment, prescribed for hyperglycemia caused by hypercortisolism in eligible adults with endogenous Cushing’s syndrome when surgery has failed or is unsuitable.
Research dated 2026-09-13.
Corcept is a commercial pharmaceutical company built around cortisol modulation, not a development-stage biotechnology company waiting for initial product revenue. Korlym is its primary marketed treatment, prescribed for hyperglycemia caused by hypercortisolism in eligible adults with endogenous Cushing’s syndrome when surgery has failed or is unsuitable.
Reported revenue therefore measures principally the commercialization of Korlym, while research spending supports relacorilant and other selective cortisol modulators across endocrine and oncology indications. This combination produces the unusual reporting shape: established product revenue and profit alongside research expenditure that remains large relative to operating income.
What do the latest results show for Corcept Therapeutics (CORT)?
Short answer · as of
The most recent reported quarter, Q2 FY2026, carried revenue of $256M.
Research dated 2026-09-13.
The latest period reversed the preceding contraction: revenue rebounded sharply, the operating loss became a profit, and operating cash flow returned to positive territory. Research expense eased from the prior period, but selling and administrative expense continued climbing; Corcept’s exceptionally high gross margin allowed much of the revenue recovery to reach operating profit despite that heavier commercial cost base.
Recent earnings have been volatile and revenue had repeatedly fallen short of market estimates before the latest result exceeded expectations. Management subsequently raised its revenue outlook and said it expects growth to continue, but that statement is guidance rather than evidence that the latest acceleration will persist.
Where is operating spending going?
Revenue alongside research and development, selling, general and administrative expenses, and the FMP standardized operating result.
- Latest quarter · revenue
- $256.15M Jun 30, 2026
- Latest quarter · R&D
- $53.89M Jun 30, 2026
- Latest quarter · SG&A
- $156.90M Jun 30, 2026
- Latest quarter · FMP standardized operating result
- $41.30M Jun 30, 2026
| Period end | Revenue | R&D | SG&A | FMP standardized operating result |
|---|---|---|---|---|
| Jun 30, 2026 | $256.15M | $53.89M | $156.90M | $41.30M |
| Mar 31, 2026 | $164.90M | $66.27M | $145.36M | −$49.60M |
| Dec 31, 2025 | $202.13M | $64.86M | $130.24M | $4.49M |
| Sep 30, 2025 | $207.64M | $68.85M | $123.98M | $10.22M |
USD. The operating result is the FMP-standardized value supplied by FMP; it may differ from a filing’s GAAP loss from operations when the provider classifies separately presented items differently. It is not net income or cash flow.
Did results meet expectations?
Reported earnings and revenue alongside the estimates recorded by the provider.
- Latest report · revenue
- $256.15M Jul 29, 2026
- Latest report · revenue estimate
- $221.15M Jul 29, 2026
- Latest report · revenue vs estimate
- Above estimate Jul 29, 2026
- Latest report · EPS vs estimate
- Above estimate Jul 29, 2026
| Report date | Revenue · reported | Revenue · estimate | EPS · reported | EPS · estimate |
|---|---|---|---|---|
| Jul 29, 2026 | $256.15M | $221.15M | $0.3600 | $0.0243 |
| Apr 30, 2026 | $164.90M | $185.27M | −$0.3000 | −$0.1102 |
| Feb 24, 2026 | $202.13M | $254.94M | $0.2000 | $0.3300 |
| Nov 4, 2025 | $207.64M | $255.35M | $0.1600 | $0.1800 |
Dates are report dates, not fiscal period ends. Revenue is in USD; EPS is USD per share, rounded to four decimals. The earnings feed does not establish a basic, diluted or adjusted basis. Earnings-feed EPS may differ from statement EPS; the two series are not combined.
Quarterly income statement — 4 quarters
| Period | Revenue | Net income | EPS |
|---|---|---|---|
| Q2 FY2026 | $256M | $42M | $0.36 (diluted) |
| Q1 FY2026 | $165M | -$31M | -$0.30 (diluted) |
| Q4 FY2025 | $202M | $24M | $0.20 (diluted) |
| Q3 FY2025 | $208M | $20M | $0.16 (diluted) |
What are the financial strengths and risks for Corcept Therapeutics (CORT)?
Short answer
Cash and short-term investments were $308.20M at the Jun 30, 2026 balance-sheet date. Operating cash flow was $33.54M for the quarter ended Jun 30, 2026, meaning operations generated cash. These figures do not establish a cash runway.
Research dated 2026-09-13.
Corcept carries substantial cash and short-term investments, minimal debt, and liquidity ratios that indicate ample coverage of near-term obligations. The marketed business has generated annual profit and operating cash flow has usually remained positive, while capital expenditure is modest.
The cash balance nevertheless ended the reported window below its opening level. More important, current economics remain concentrated in Korlym while research and commercial expenses consume a large share of gross profit; weaker Korlym demand would therefore pressure earnings and internal pipeline funding at the same time. The market value stands far above net cash, so balance-sheet strength offers limited protection against a reassessment of expected growth.
Data-derived red flags
- Inconsistent delivery — missed Wall Street EPS estimates in 4 of the last 8 reported quarters.
- Rich valuation — a P/E of 223.52 runs well above the Healthcare sector’s ~21.10x, leaving little room for a miss.
How much cash does the business generate or use?
Quarterly operating cash flow shows cash generated or used by operations.
- Latest quarter · operating cash flow
- $33.54M Jun 30, 2026
- Previous quarter · operating cash flow
- −$16.77M Mar 31, 2026
| Period end | Operating cash flow | Capital expenditure (reported) |
|---|---|---|
| Jun 30, 2026 | $33.54M | −$2.53M |
| Mar 31, 2026 | −$16.77M | −$200,000 |
| Dec 31, 2025 | $38.45M | −$50,000 |
| Sep 30, 2025 | $54.48M | $0.00 |
Operating cash-flow bars share one scale and show magnitude; negative values mean cash used.
USD. Negative operating cash flow means cash used. Capital expenditure keeps the provider’s reported sign; it is not added here to estimate free cash flow or runway.
What should you watch next at Corcept Therapeutics (CORT)?
Short answer · as of
The next earnings report is expected on Nov 4, 2026.
Research dated 2026-09-13.
At the scheduled earnings release, compare revenue with the elevated market estimate and examine whether operating profit and cash generation hold as selling and administrative spending expands. Confirmation would be continued revenue strength with positive operating cash flow; renewed revenue weakness alongside rising expenses would challenge the latest recovery.
Management’s raised outlook also needs support from reported sales rather than guidance alone. Beyond the near-term result, the widening range of longer-horizon revenue estimates shows that expectations depend heavily on how far Corcept can extend its cortisol franchise, making progress around relacorilant commercially consequential.
What management is planning
Management expectations, not completed milestones or guarantees. Selected verbatim excerpts; dates follow the transcript provider.
We expect growth to continue and have increased our 2026 revenue guidance to a range of $1.1 billion to $1.2 billion Net income was $43 million in the second quarter of 26, compared to net income of $35 million in the prior year period.
Atabak Mokari ·
How does Corcept Therapeutics compare with its peers?
Short answer
Corcept Therapeutics's score ranks 2nd of 13 in the bounded comparison shown, against 12 same-model peers. These are company scores, not expected investment returns. The set lists named competitors first, then companies in the same data-provider industry classification closest in market value; that classification is the provider's, not our judgment of business similarity.
Research dated 2026-09-13.
Corcept sits between a mature specialty-drug company and a pipeline-focused biotechnology business. Korlym already supports high gross profit, annual earnings, and internal cash generation, while relacorilant and other cortisol modulators create development optionality without making the company dependent on external financing for routine operations.
That profile differs from a diversified pharmaceutical company because current commercial exposure is concentrated in Korlym and much of the pipeline remains tied to cortisol biology. It also differs from a pre-commercial peer because product demand, commercial spending, and operating cash flow already determine near-term results. Investors are therefore evaluating execution in an existing Cushing’s franchise together with the prospect of broader endocrine and oncology uses.
| Company | Price | Market value | Score |
|---|---|---|---|
| $358.07 Oct 2, 2026 | $38.3B | 96 5-pillar Oct 4, 2026 | |
| Corcept Therapeutics (CORT) — this page | $116.23 | $12.6B | 91 |
| $109.86 Oct 2, 2026 | $13.0B | 88 5-pillar Oct 4, 2026 | |
| $20.65 Oct 2, 2026 | $1.27B | 56 5-pillar Oct 4, 2026 | |
| $15.51 Oct 2, 2026 | $953M | 56 5-pillar Oct 4, 2026 | |
| $235.67 Oct 2, 2026 | $14.8B | 40 5-pillar Oct 4, 2026 | |
| $3.22 Oct 2, 2026 | $28.1M | 39 5-pillar Oct 4, 2026 | |
| $2.63 Oct 2, 2026 | $231M | 38 5-pillar Oct 4, 2026 | |
| $179.25 Oct 2, 2026 | $9.22B | 33 5-pillar Oct 4, 2026 | |
| $1.36 Oct 2, 2026 | $29.1M | 32 5-pillar Oct 4, 2026 | |
| $0.80 Oct 2, 2026 | $22.4M | 28 5-pillar Oct 4, 2026 | |
| $6.31 Oct 2, 2026 | $25.5M | 27 5-pillar Oct 4, 2026 | |
| $22.74 Oct 2, 2026 | $155M | 20 5-pillar Oct 4, 2026 |
Only 5-pillar scores are ranked together. Other models are not directly comparable. Price and score dates are shown separately; market-value dates are unavailable.
The records behind this page
Analyst targets & estimates
What analysts have on file
- Price target, low to high
- $50.00 – $165.00
- Consensus target
- $125.33
- Median target
- $142.50
Consensus record · Captured .
Measured against a quoted price of $116.23 (as of Oct 2, 2026).
Insider activity
Form 4 records via FMP · Of the newest 100 records, those within the last 180 days, newest dated Sep 24, 2026
- Transactions
- 96
- Identified insiders
- 9
- Purchases
- 0
- Sales
- 47
- Other transactions
- 49
Purchases and sales use the reported transaction category. Other transactions include awards, exercises, gifts, withholding and unclassified activity; an acquisition or disposition alone is not a purchase or sale. These records do not establish intent.
Who holds the shares?
Institutional ownership reported through 13F filings.
- Institutional ownership
- 79.3% Period end Jun 30, 2026
- Previous quarter · ownership
- 76.2% Prior to period end Jun 30, 2026
- Reporting holders
- 451 Period end Jun 30, 2026
- Previous quarter · holders
- 370 Prior to period end Jun 30, 2026
| Holders in provider snapshot | Shares |
|---|---|
| Blackrock, INC. | 12,432,023 |
| Ingalls & Snyder LLC | 7,934,507 |
| Renaissance Technologies LLC | 5,261,628 |
| Vanguard Portfolio Management LLC | 5,044,638 |
| Vanguard Capital Management LLC | 4,172,482 |
Quarterly filings lag the period end. Holder rows are names in the provider snapshot, not a verified ranking; individual filing dates are not supplied. Related managers may appear separately, so these positions are not summed. Holder snapshot as of Jun 30, 2026.
What has been published about Corcept Therapeutics (CORT)?
Common Questions About CORT (Healthcare)
Research dated 2026-09-13; the answers below are from that research, and the full attribution is under Sources. The last 2 questions are answered from this page's own dated data, not from the research.
Is Korlym still Corcept’s commercial engine?
Korlym remains Corcept’s primary commercial offering, so reported revenue principally reflects demand for its use in eligible adults with Cushing’s syndrome. The pipeline broadens the opportunity set but does not yet replace Korlym as the foundation of current economics.
How could relacorilant change Corcept’s business?
Relacorilant is being developed for Cushing’s syndrome and, with nab-paclitaxel, for advanced ovarian tumors. Successful commercialization could reduce reliance on Korlym and extend Corcept’s cortisol-modulation franchise into oncology.
Why did Corcept return to profit after its recent loss?
Revenue recovered sharply while research expense eased, more than offsetting continued growth in selling and administrative costs. Corcept’s very high gross margin amplified the effect of that revenue rebound on operating profit and cash flow.
Can Korlym fund Corcept’s cortisol-modulator pipeline?
The marketed business has produced annual profit and generally positive operating cash flow, while substantial liquidity and minimal debt provide additional capacity. Rising research and commercial expenses mean that continued Korlym demand remains important to preserving that self-funded model.
What is the CORT stock price today?
The last price recorded on this page for Corcept Therapeutics Incorporated (CORT) is $116.23, as of the Oct 2, 2026 trading session (source: Financial Modeling Prep (FMP) · quote). It is a provider snapshot, not a live exchange feed, so check a brokerage quote before you trade.
What is the CORT price target?
The analyst consensus price target for Corcept Therapeutics Incorporated (CORT) is $125.33 (range $50.00 to $165.00, median $142.50), per FMP data captured Oct 4, 2026. Targets are analyst opinions and change often; they are not a Stock Expert AI forecast.
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Research written by Codex (gpt-5.6-sol) on 2026-09-13. AI-authored analysis; source dates are shown with each answer. Editorial oversight is systemic, not page-by-page. Editorially accountable: Sedat ANAK, Founder and Editor-in-Chief.
Sources — records for every figure on this page (83 figures)
The 83 rows below are exactly the facts the evidence-backed sections of this page printed — the 10-second verdict, the MoonshotScore, price and market value, the five questions with their receipts, and the records behind this page. Known dates and sources are recorded on their own rows; an em dash or UNRECORDED tier preserves a stored observation without inventing either. The quarterly income statement is provider-standardized (FMP) under one row, and scale definitions — a 0-100 rating, the band ladder, the Piotroski 0–9 range — are fixed rather than measured. No number in those sections was generated by a model. The register does not cover quoted third-party headlines, the dated council readings, or the Frequently Asked Questions; each of those says where it came from where it stands.
"As of" is the date the value is true for where the source carries one — a quarter end, a filing date, a price close, the day the score was computed. A cached observation with no source date remains undated; the page publication date is not used as a substitute.
OFFICIAL — 2 facts from SEC filings and earnings calls
| Fact ID | Fact | Value as shown | As of | Tier | Source |
|---|---|---|---|---|---|
prod.outlook | Management outlook — call excerpts | Atabak Mokari (Jul 29, 2026): We expect growth to continue and have increased our 2026 revenue guidance to a range of $1.1 billion to $1.2 billion Net income was $43 million in the second quarter of 26, compared to net income of $35 million in the prior year period. | OFFICIAL | Company earnings call, transcript via Financial Modeling Prep (FMP) — Selected verbatim statements from the latest available call, dated by the transcript provider. Management expectations, not completed milestones or guarantees. Relative dates retain the speaker's wording. | |
id.hq | SEC filing business address | Redwood City, CA | OFFICIAL | SEC EDGAR filer business address — The SEC filer business address. Our market-data provider separately lists "101 Redwood Shores Parkway, Redwood City, CA, 94065, US". The FMP company description names Menlo Park, California as the headquarters; this page uses the address in this row. |
FMP — 73 facts from Financial Modeling Prep endpoint families
| Fact ID | Fact | Value as shown | As of | Tier | Source |
|---|---|---|---|---|---|
earn.next | Next earnings date | Nov 4, 2026 | FMP | Financial Modeling Prep (FMP) earnings calendar — The date is our provider's estimate until the company confirms it. | |
px.last | Latest provided price | $116.23 | FMP | Financial Modeling Prep (FMP) · quote — Dated to the US trading session the price belongs to, derived from the quote record's timestamp (weekend and pre-open reads roll back to the previous weekday; exchange holidays are not modelled). The record does not establish an exchange execution time. Retrieved 2026-10-04T05:14:20.567Z. | |
px.change | Change on the day | +1.93% | FMP | Financial Modeling Prep (FMP) · quote | |
px.mcap | Market capitalisation | $12.6B | FMP | Financial Modeling Prep (FMP) · quote — Date unknown Market cap record date: 2026-10-02. FMP quote timestamp: 2026-10-02T20:00:01.000Z. Captured from FMP at 2026-10-04T05:14:19.248Z. No share-count basis is inferred; this page preserves the reported amount instead of recalculating it from shares. | |
px.change_abs | Change on the day, in dollars | +$2.21 | FMP | Financial Modeling Prep (FMP) · quote | |
fin.q_revenue | Revenue, Q2 FY2026 | $256M | FMP | Financial Modeling Prep (FMP) · income statement (quarterly) | |
px.range52 | 52-week range | $28.66–$126.38 | FMP | Financial Modeling Prep (FMP) quote | |
px.pe | Price / earnings (trailing) | 223.52 | FMP | Financial Modeling Prep (FMP) · quote | |
px.volume | Shares traded on the day | 930.2K | FMP | Financial Modeling Prep (FMP) · quote | |
px.beta | Beta | 0.45 | FMP | Financial Modeling Prep (FMP) company profile | |
id.ceo | Chief executive | Joseph K. Belanoff | FMP | Financial Modeling Prep (FMP) key executives (proxy-derived) — Titles and pay come from the company's proxy statement as our provider parsed it. | |
id.employees | Employees | 730 | FMP | Financial Modeling Prep (FMP) employee count, from the company's filing | |
fin.annual | Revenue and net result by fiscal year | 5 fiscal years, FY2021 through FY2025: FY2021 revenue $365.98M, net result $112.51M; FY2022 revenue $401.86M, net result $101.42M; FY2023 revenue $482.38M, net result $106.14M; FY2024 revenue $675.04M, net result $139.73M; FY2025 revenue $761.41M, net result $99.65M | FMP | Financial Modeling Prep (FMP), from the company's 10-K income statements | |
fin.gross_margin | Gross margin (trailing twelve months) | 98.3% | FMP | Financial Modeling Prep (FMP) key-metrics-ttm + ratios-ttm — A ratio our provider could not compute is absent rather than shown as zero. | |
fin.q_table.depth.2026-06-30.revenue_k | Revenue — period end 2026-06-30 | $256.15M | Period end · | FMP | Financial Modeling Prep (FMP), from the company's 10-Q and 10-K income statements — Quarterly statement note |
fin.q_table.depth.2026-06-30.rd_k | R&D — period end 2026-06-30 | $53.89M | Period end · | FMP | Financial Modeling Prep (FMP), from the company's 10-Q and 10-K income statements — Quarterly statement note |
fin.q_table.depth.2026-06-30.sga_k | SG&A — period end 2026-06-30 | $156.90M | Period end · | FMP | Financial Modeling Prep (FMP), from the company's 10-Q and 10-K income statements — Quarterly statement note |
fin.q_table.depth.2026-06-30.operating_result_k | FMP standardized operating result — period end 2026-06-30 | $41.30M | Period end · | FMP | Financial Modeling Prep (FMP), from the company's 10-Q and 10-K income statements — Quarterly statement note |
fin.q_table.depth.2026-03-31.revenue_k | Revenue — period end 2026-03-31 | $164.90M | Period end · | FMP | Financial Modeling Prep (FMP), from the company's 10-Q and 10-K income statements — Quarterly statement note |
fin.q_table.depth.2026-03-31.rd_k | R&D — period end 2026-03-31 | $66.27M | Period end · | FMP | Financial Modeling Prep (FMP), from the company's 10-Q and 10-K income statements — Quarterly statement note |
fin.q_table.depth.2026-03-31.sga_k | SG&A — period end 2026-03-31 | $145.36M | Period end · | FMP | Financial Modeling Prep (FMP), from the company's 10-Q and 10-K income statements — Quarterly statement note |
fin.q_table.depth.2026-03-31.operating_result_k | FMP standardized operating result — period end 2026-03-31 | −$49.60M | Period end · | FMP | Financial Modeling Prep (FMP), from the company's 10-Q and 10-K income statements — Quarterly statement note |
fin.q_table.depth.2025-12-31.revenue_k | Revenue — period end 2025-12-31 | $202.13M | Period end · | FMP | Financial Modeling Prep (FMP), from the company's 10-Q and 10-K income statements — Quarterly statement note |
fin.q_table.depth.2025-12-31.rd_k | R&D — period end 2025-12-31 | $64.86M | Period end · | FMP | Financial Modeling Prep (FMP), from the company's 10-Q and 10-K income statements — Quarterly statement note |
fin.q_table.depth.2025-12-31.sga_k | SG&A — period end 2025-12-31 | $130.24M | Period end · | FMP | Financial Modeling Prep (FMP), from the company's 10-Q and 10-K income statements — Quarterly statement note |
fin.q_table.depth.2025-12-31.operating_result_k | FMP standardized operating result — period end 2025-12-31 | $4.49M | Period end · | FMP | Financial Modeling Prep (FMP), from the company's 10-Q and 10-K income statements — Quarterly statement note |
fin.q_table.depth.2025-09-30.revenue_k | Revenue — period end 2025-09-30 | $207.64M | Period end · | FMP | Financial Modeling Prep (FMP), from the company's 10-Q and 10-K income statements — Quarterly statement note |
fin.q_table.depth.2025-09-30.rd_k | R&D — period end 2025-09-30 | $68.85M | Period end · | FMP | Financial Modeling Prep (FMP), from the company's 10-Q and 10-K income statements — Quarterly statement note |
fin.q_table.depth.2025-09-30.sga_k | SG&A — period end 2025-09-30 | $123.98M | Period end · | FMP | Financial Modeling Prep (FMP), from the company's 10-Q and 10-K income statements — Quarterly statement note |
fin.q_table.depth.2025-09-30.operating_result_k | FMP standardized operating result — period end 2025-09-30 | $10.22M | Period end · | FMP | Financial Modeling Prep (FMP), from the company's 10-Q and 10-K income statements — Quarterly statement note |
earn.history.depth.2026-07-29.revenue_actual | Revenue · reported — report date 2026-07-29 | $256.15M | Report date · | FMP | Financial Modeling Prep (FMP) earnings — Earnings-history note |
earn.history.depth.2026-07-29.revenue_estimated | Revenue · estimate — report date 2026-07-29 | $221.15M | Report date · | FMP | Financial Modeling Prep (FMP) earnings — Earnings-history note |
earn.history.depth.2026-07-29.eps_actual | EPS · reported — report date 2026-07-29 | $0.3600 | Report date · | FMP | Financial Modeling Prep (FMP) earnings — Earnings-history note |
earn.history.depth.2026-07-29.eps_estimated | EPS · estimate — report date 2026-07-29 | $0.0243 | Report date · | FMP | Financial Modeling Prep (FMP) earnings — Earnings-history note |
earn.history.depth.2026-04-30.revenue_actual | Revenue · reported — report date 2026-04-30 | $164.90M | Report date · | FMP | Financial Modeling Prep (FMP) earnings — Earnings-history note |
earn.history.depth.2026-04-30.revenue_estimated | Revenue · estimate — report date 2026-04-30 | $185.27M | Report date · | FMP | Financial Modeling Prep (FMP) earnings — Earnings-history note |
earn.history.depth.2026-04-30.eps_actual | EPS · reported — report date 2026-04-30 | −$0.3000 | Report date · | FMP | Financial Modeling Prep (FMP) earnings — Earnings-history note |
earn.history.depth.2026-04-30.eps_estimated | EPS · estimate — report date 2026-04-30 | −$0.1102 | Report date · | FMP | Financial Modeling Prep (FMP) earnings — Earnings-history note |
earn.history.depth.2026-02-24.revenue_actual | Revenue · reported — report date 2026-02-24 | $202.13M | Report date · | FMP | Financial Modeling Prep (FMP) earnings — Earnings-history note |
earn.history.depth.2026-02-24.revenue_estimated | Revenue · estimate — report date 2026-02-24 | $254.94M | Report date · | FMP | Financial Modeling Prep (FMP) earnings — Earnings-history note |
earn.history.depth.2026-02-24.eps_actual | EPS · reported — report date 2026-02-24 | $0.2000 | Report date · | FMP | Financial Modeling Prep (FMP) earnings — Earnings-history note |
earn.history.depth.2026-02-24.eps_estimated | EPS · estimate — report date 2026-02-24 | $0.3300 | Report date · | FMP | Financial Modeling Prep (FMP) earnings — Earnings-history note |
earn.history.depth.2025-11-04.revenue_actual | Revenue · reported — report date 2025-11-04 | $207.64M | Report date · | FMP | Financial Modeling Prep (FMP) earnings — Earnings-history note |
earn.history.depth.2025-11-04.revenue_estimated | Revenue · estimate — report date 2025-11-04 | $255.35M | Report date · | FMP | Financial Modeling Prep (FMP) earnings — Earnings-history note |
earn.history.depth.2025-11-04.eps_actual | EPS · reported — report date 2025-11-04 | $0.1600 | Report date · | FMP | Financial Modeling Prep (FMP) earnings — Earnings-history note |
earn.history.depth.2025-11-04.eps_estimated | EPS · estimate — report date 2025-11-04 | $0.1800 | Report date · | FMP | Financial Modeling Prep (FMP) earnings — Earnings-history note |
fin.q_table | Quarterly income statement | 4 quarters through Q2 FY2026 | FMP | Financial Modeling Prep (FMP) · income statement (quarterly), as filed | |
fin.cash_investments | Cash and short-term investments | $308.20M | FMP | Financial Modeling Prep (FMP), from the company's balance sheet — Long-term investments are shown separately; their marketability is not established by the provider field. The cash and short-term investment balance does not establish unrestricted availability. Long-term investments are excluded and remain unclassified. Restrictions on cash and short-term investments require separate review. | |
fin.opcf_latest | Latest-quarter operating cash flow | $33.54M | FMP | Financial Modeling Prep (FMP), from the company's 10-Q cash-flow statements — Period end: 2026-06-30. Negative operating cash flow means cash used. This figure is not a cash-runway estimate. | |
fin.long_term_investments | Long-term investments (classification unverified) | $0.00 | FMP | Financial Modeling Prep (FMP), from the company's balance sheet — Long-term investments are shown separately; their marketability is not established by the provider field. The cash and short-term investment balance does not establish unrestricted availability. | |
fin.total_debt | Total debt | $9.42M | FMP | Financial Modeling Prep (FMP), from the company's balance sheet — Long-term investments are shown separately; their marketability is not established by the provider field. The cash and short-term investment balance does not establish unrestricted availability. | |
fin.price_to_book | Price to book value | 17.35× | FMP | Financial Modeling Prep (FMP) key-metrics-ttm + ratios-ttm — A ratio our provider could not compute is absent rather than shown as zero. | |
fin.opcf.depth.2026-06-30.operating_cash_flow_m | Operating cash flow — period end 2026-06-30 | $33.54M | Period end · | FMP | Financial Modeling Prep (FMP), from the company's 10-Q cash-flow statements — Cash-flow note |
fin.opcf.depth.2026-03-31.operating_cash_flow_m | Operating cash flow — period end 2026-03-31 | −$16.77M | Period end · | FMP | Financial Modeling Prep (FMP), from the company's 10-Q cash-flow statements — Cash-flow note |
fin.opcf.depth.2026-06-30.capex_m | Capital expenditure (reported) — period end 2026-06-30 | −$2.53M | Period end · | FMP | Financial Modeling Prep (FMP), from the company's 10-Q cash-flow statements — Cash-flow note |
fin.opcf.depth.2026-03-31.capex_m | Capital expenditure (reported) — period end 2026-03-31 | −$200,000 | Period end · | FMP | Financial Modeling Prep (FMP), from the company's 10-Q cash-flow statements — Cash-flow note |
fin.opcf.depth.2025-12-31.operating_cash_flow_m | Operating cash flow — period end 2025-12-31 | $38.45M | Period end · | FMP | Financial Modeling Prep (FMP), from the company's 10-Q cash-flow statements — Cash-flow note |
fin.opcf.depth.2025-12-31.capex_m | Capital expenditure (reported) — period end 2025-12-31 | −$50,000 | Period end · | FMP | Financial Modeling Prep (FMP), from the company's 10-Q cash-flow statements — Cash-flow note |
fin.opcf.depth.2025-09-30.operating_cash_flow_m | Operating cash flow — period end 2025-09-30 | $54.48M | Period end · | FMP | Financial Modeling Prep (FMP), from the company's 10-Q cash-flow statements — Cash-flow note |
fin.opcf.depth.2025-09-30.capex_m | Capital expenditure (reported) — period end 2025-09-30 | $0.00 | Period end · | FMP | Financial Modeling Prep (FMP), from the company's 10-Q cash-flow statements — Cash-flow note |
earn.pt_range | Analyst price target, low to high | $50.00 – $165.00 | FMP | Financial Modeling Prep (FMP) · price-target consensus — Captured Oct 4, 2026 · Coverage not supplied | |
earn.pt_consensus | Consensus analyst price target | $125.33 | FMP | Financial Modeling Prep (FMP) · price-target consensus — Captured Oct 4, 2026 · Coverage not supplied | |
earn.pt_median | Median analyst price target | $142.50 | FMP | Financial Modeling Prep (FMP) · price-target consensus — Captured Oct 4, 2026 · Coverage not supplied | |
own.insiders | Insider transactions via FMP | 96 transactions · 0 purchases, 47 sales, 49 other transactions · 9 identified insiders · of the newest 100 records, those within the last 180 days, newest dated Sep 24, 2026 | FMP | Financial Modeling Prep (FMP), carrying Form 4 transaction records — Purchases and sales use the reported transaction category. Other transactions include awards, exercises, gifts, withholding and unclassified activity; an acquisition or disposition alone is not a purchase or sale. These records do not establish intent. | |
own.institutions.depth.ownership_pct | Institutional ownership | 79.3% | FMP | Financial Modeling Prep (FMP) institutional ownership summary, from 13F filings — 13F filings are quarterly and lag the quarter end by up to 45 days. Period end Jun 30, 2026 | |
own.institutions.depth.ownership_pct_previous_quarter | Previous quarter · ownership | 76.2% | FMP | Financial Modeling Prep (FMP) institutional ownership summary, from 13F filings — 13F filings are quarterly and lag the quarter end by up to 45 days. Prior to period end Jun 30, 2026 | |
own.institutions.depth.holders | Reporting holders | 451 | FMP | Financial Modeling Prep (FMP) institutional ownership summary, from 13F filings — 13F filings are quarterly and lag the quarter end by up to 45 days. Period end Jun 30, 2026 | |
own.institutions.depth.holders_previous_quarter | Previous quarter · holders | 370 | FMP | Financial Modeling Prep (FMP) institutional ownership summary, from 13F filings — 13F filings are quarterly and lag the quarter end by up to 45 days. Prior to period end Jun 30, 2026 | |
own.top_holders.depth.holder_0.shares | Blackrock, INC. — shares in provider snapshot | 12,432,023 | FMP | Financial Modeling Prep (FMP) institutional holders, from 13F filings — Provider snapshot as of 2026-06-30; individual filing date not supplied. | |
own.top_holders.depth.holder_1.shares | Ingalls & Snyder LLC — shares in provider snapshot | 7,934,507 | FMP | Financial Modeling Prep (FMP) institutional holders, from 13F filings — Provider snapshot as of 2026-06-30; individual filing date not supplied. | |
own.top_holders.depth.holder_2.shares | Renaissance Technologies LLC — shares in provider snapshot | 5,261,628 | FMP | Financial Modeling Prep (FMP) institutional holders, from 13F filings — Provider snapshot as of 2026-06-30; individual filing date not supplied. | |
own.top_holders.depth.holder_3.shares | Vanguard Portfolio Management LLC — shares in provider snapshot | 5,044,638 | FMP | Financial Modeling Prep (FMP) institutional holders, from 13F filings — Provider snapshot as of 2026-06-30; individual filing date not supplied. | |
own.top_holders.depth.holder_4.shares | Vanguard Capital Management LLC — shares in provider snapshot | 4,172,482 | FMP | Financial Modeling Prep (FMP) institutional holders, from 13F filings — Provider snapshot as of 2026-06-30; individual filing date not supplied. |
UNRECORDED — 2 facts from stored observations whose source was not recorded
| Fact ID | Fact | Value as shown | As of | Tier | Source |
|---|---|---|---|---|---|
earn.history | Reported versus estimated, recent quarters | EPS beat 3 of 8 | UNRECORDED | Stored earnings-history observation — Captured 2026-09-24 · Expired observation | |
fin.scores | Distress and quality screens | Altman Z 43.66 · Piotroski F 6 | UNRECORDED | Stored financial-scores observation — Captured 2026-10-03 · Expired observation |
COMPUTED — 3 facts from our arithmetic, formula restated
| Fact ID | Fact | Value as shown | As of | Tier | Source |
|---|---|---|---|---|---|
fin.mcap_to_cash | Market value per dollar of cash and short-term investments | 40.88× | — | COMPUTED | Computed on this page from the figures above — The market capitalisation printed on this page divided by cash and short-term investments of $308.20M at Jun 30, 2026. Long-term investments are excluded and remain unclassified. Restrictions on cash and short-term investments require separate review. Market cap record date: 2026-10-02. Balance-sheet reference date: 2026-06-30. The inputs do not establish a single common source date for this ratio. |
earn.history.depth.2026-07-29.revenue_actual.comparison | Latest report · revenue vs estimate | Above estimate | Report date · | COMPUTED | Computed from Financial Modeling Prep (FMP) earnings — Earnings-history note — Method: compare reported revenue ($256.15M) with the recorded estimate ($221.15M) at displayed precision. Equal displayed values are in line. This compares reported results with recorded estimates, not investment returns. |
earn.history.depth.2026-07-29.eps_actual.comparison | Latest report · EPS vs estimate | Above estimate | Report date · | COMPUTED | Computed from Financial Modeling Prep (FMP) earnings — Earnings-history note — Method: compare reported EPS ($0.3600) with the recorded estimate ($0.0243) at displayed precision. Equal displayed values are in line. This compares reported results with recorded estimates, not investment returns. |
OURS — 3 facts from Stock Expert AI's own score and rank
| Fact ID | Fact | Value as shown | As of | Tier | Source |
|---|---|---|---|---|---|
ours.moonshot | MoonshotScore v2 | 91 of 100 · Exceptional · pillars 89 / 96 / 31 / 36 / 95 | OURS | Stock Expert AI MoonshotScore v2 engine | |
ours.valuation_driver | Recorded valuation score driver | Enterprise value relative to EBITDA is the main valuation drag relative to sector peers. | OURS | Stock Expert AI MoonshotScore v2 engine · stored factor contributions | |
ours.moonshot_change | MoonshotScore movement | 91 (stored snapshot Oct 3, 2026) → 91 (current publication computed Oct 4, 2026) (0) | OURS | Stock Expert AI current score publication and immutable score snapshots |
Fact-family notes
- Quarterly statement note. Source series as of 2026-06-30. USD. The operating result is the FMP-standardized value supplied by FMP; it may differ from a filing’s GAAP loss from operations when the provider classifies separately presented items differently. It is not net income or cash flow. Applies to Fact IDs:
fin.q_table.depth.2026-06-30.revenue_k,fin.q_table.depth.2026-06-30.rd_k,fin.q_table.depth.2026-06-30.sga_k,fin.q_table.depth.2026-06-30.operating_result_k,fin.q_table.depth.2026-03-31.revenue_k,fin.q_table.depth.2026-03-31.rd_k,fin.q_table.depth.2026-03-31.sga_k,fin.q_table.depth.2026-03-31.operating_result_k,fin.q_table.depth.2025-12-31.revenue_k,fin.q_table.depth.2025-12-31.rd_k,fin.q_table.depth.2025-12-31.sga_k,fin.q_table.depth.2025-12-31.operating_result_k,fin.q_table.depth.2025-09-30.revenue_k,fin.q_table.depth.2025-09-30.rd_k,fin.q_table.depth.2025-09-30.sga_k,fin.q_table.depth.2025-09-30.operating_result_k. - Earnings-history note. Source series as of 2026-07-29. Dates are report dates, not fiscal period ends. Revenue is in USD; EPS is USD per share, rounded to four decimals. The earnings feed does not establish a basic, diluted or adjusted basis. Earnings-feed EPS may differ from statement EPS; the two series are not combined. Applies to Fact IDs:
earn.history.depth.2026-07-29.revenue_actual,earn.history.depth.2026-07-29.revenue_estimated,earn.history.depth.2026-07-29.revenue_actual.comparison,earn.history.depth.2026-07-29.eps_actual.comparison,earn.history.depth.2026-07-29.eps_actual,earn.history.depth.2026-07-29.eps_estimated,earn.history.depth.2026-04-30.revenue_actual,earn.history.depth.2026-04-30.revenue_estimated,earn.history.depth.2026-04-30.eps_actual,earn.history.depth.2026-04-30.eps_estimated,earn.history.depth.2026-02-24.revenue_actual,earn.history.depth.2026-02-24.revenue_estimated,earn.history.depth.2026-02-24.eps_actual,earn.history.depth.2026-02-24.eps_estimated,earn.history.depth.2025-11-04.revenue_actual,earn.history.depth.2025-11-04.revenue_estimated,earn.history.depth.2025-11-04.eps_actual,earn.history.depth.2025-11-04.eps_estimated. - Cash-flow note. Source series as of 2026-06-30. USD. Negative operating cash flow means cash used. Capital expenditure keeps the provider’s reported sign; it is not added here to estimate free cash flow or runway. Applies to Fact IDs:
fin.opcf.depth.2026-06-30.operating_cash_flow_m,fin.opcf.depth.2026-03-31.operating_cash_flow_m,fin.opcf.depth.2026-06-30.capex_m,fin.opcf.depth.2026-03-31.capex_m,fin.opcf.depth.2025-12-31.operating_cash_flow_m,fin.opcf.depth.2025-12-31.capex_m,fin.opcf.depth.2025-09-30.operating_cash_flow_m,fin.opcf.depth.2025-09-30.capex_m.
- Published
- Research standards
- Methodology · Editorial policy · Corrections
- Report a number
- sedat@stockexpertai.com
Sources used for research written 2026-09-13
Historical evidence preserved with this analysis. Current figures are listed separately above.
| Evidence | Captured value | Source date | Source type | Source |
|---|---|---|---|---|
| Legal name | CORCEPT THERAPEUTICS INC Our market-data provider lists the name as "Corcept Therapeutics Incorporated"; the filer's own record is used here. | 2026-02-24 | OFFICIAL | SEC EDGAR — 10-K filed 2026-02-24 |
| Business description | Corcept Therapeutics Incorporated, founded in 1998 and headquartered in Menlo Park, California, is a pharmaceutical firm dedicated to the discovery, development, and commercialization of treatments for serious metabolic, oncological, and neuropsychiatric disorders across the United States. Its primary commercial offering is Korlym (mifepristone) tablets, an oral medication taken once daily. Korlym is prescribed for adult patients diagnosed with endogenous Cushing's syndrome who suffer from hyperglycemia due to hypercortisolism, particularly those with type 2 diabetes or glucose intolerance, and for whom surgical options have either failed or are not viable. The company's development pipeline is robust, featuring relacorilant, which is being advanced for Cushing's syndrome. It is also investigating a combination of relacorilant with nab-paclitaxel; this pairing has concluded Phase II clinical trials for advanced ovarian tumors and is additionally being studied for conditions involving cortisol excess. Furthermore, Corcept is developing distinct selective cortisol modulators for specific indications such as metastatic castration-resistant prostate cancer and antipsychotic-induced weight gain, alongside research into FKBP5 gene expression assays. | 2026-09-13 | FMP | Financial Modeling Prep (FMP) company profile |
| Quarterly income statement (USD thousands) | Captured record · 8 entries
| 2026-06-30 | FMP | Financial Modeling Prep (FMP), from the company's 10-Q and 10-K income statements |
| Trailing twelve-month ratio set | Quick ratio: 2.77; Current ratio: 2.86; Debt to equity: 0.01; Net margin: 6.6%; Gross margin: 98.3%; Operating margin: 0.8%; Return on assets: 6.2%; Return on equity: 8.4% Price-based multiples captured at research time are not repeated here; the page shows each once, from current figures with their own dates. A ratio our provider could not compute is absent rather than shown as zero. | 2026-09-13 | FMP | Financial Modeling Prep (FMP) key-metrics-ttm + ratios-ttm |
| Analyst revenue and earnings estimates (average) | Captured record · 4 entries
| 2026-09-13 | FMP | Financial Modeling Prep (FMP) analyst estimates |
| Sector / industry (provider taxonomy) | Healthcare / Medical - Pharmaceuticals The company's SEC filings classify it under SIC 2834 — Pharmaceutical Preparations. | 2026-09-13 | FMP | Financial Modeling Prep (FMP) company profile |
| Annual revenue and net result (USD millions) | Captured record · 5 entries
| 2025-12-31 | FMP | Financial Modeling Prep (FMP), from the company's 10-K income statements |
| Operating cash flow by quarter (USD millions) | Captured record · 8 entries
| 2026-06-30 | FMP | Financial Modeling Prep (FMP), from the company's 10-Q cash-flow statements |
| Reported versus estimated, last 8 quarters | Captured record · 8 entries
| 2026-07-29 | FMP | Financial Modeling Prep (FMP) earnings |
| Management outlook — dated call excerpts | Captured record · 1 entry
Selected verbatim statements from the latest available call, dated by the transcript provider. Management expectations, not completed milestones or guarantees. Relative dates retain the speaker's wording. | 2026-07-29 | OFFICIAL | Company earnings call, transcript via Financial Modeling Prep (FMP) |
| Cash, investments and debt | Total debt: $9.42M; Liquidity basis: cash and short-term investments; Total liabilities: $182.93M; Cash and short-term investments: $308.20M; Cash and investments: $308.20M; Long-term investments: $0; Long-term investments classification: unclassified Long-term investments are shown separately; their marketability is not established by the provider field. The cash and short-term investment balance does not establish unrestricted availability. | 2026-06-30 | FMP | Financial Modeling Prep (FMP), from the company's balance sheet |
| Cash and investment components | Total basis: cash short and long-term investments; Total: $308.20M; Cash and short-term investments: $308.20M; Long-term investments: $0; Long-term investments classification: unclassified Sums the balance sheet's cash and short-term investments with its long-term investments.; The long-term investment field does not establish marketability; the sum is not a measure of available liquidity.; These provider fields do not establish investment access restrictions or explain differences from third-party cash figures. | 2026-06-30 | COMPUTED | Computed from the balance sheet |
| Cash and short-term investments over time (USD millions) | Captured record · 8 entries
| 2026-06-30 | FMP | Financial Modeling Prep (FMP), from the company's quarterly balance sheets |
| Cash decline over the reported window | To: 2026-06-30; From: 2024-09-30; Periods: 7; Cash basis: cash and short-term investments; Closing balance: $308.20M; Decline: $72.10M; Opening balance: $380.30M; Average change per period: $10.30M Change in cash, cash equivalents and short-term investments between the 2024-09-30 and 2026-06-30 balance sheets.; This is a balance change, not operating burn: financing and investing move it too.; Averaged over 7 reporting periods of unequal length. | 2026-06-30 | COMPUTED | Computed from reported balances |
| Cash against market value | As of: 2026-06-30; Cash basis: cash and short-term investments; Net cash: $298.80M; Total debt: $9.40M; Cash and investments: $308.20M Price-based multiples captured at research time are not repeated here; the page shows each once, from current figures with their own dates. Cash is the latest reported cash and short-term investment balance; long-term investments are excluded. Market capitalization is the latest provider value.; The reported balance does not establish unrestricted availability or liquidation value.; The two are measured on different dates — the balance sheet is a quarter-end, the market cap is a recent close.; Debt is total debt as reported, including operating lease liabilities where the filer includes them. | 2026-06-30 | COMPUTED | Computed from the balance sheet and the latest market capitalization |
| Distress and quality screens | Altman Z-score: 42.44; Piotroski F-score: 6 Altman Z below 1.8 is the conventional distress zone. The screen is built for manufacturers and industrials; for banks, insurers and property companies it is not a meaningful reading. | 2026-09-13 | FMP | Financial Modeling Prep (FMP) financial scores |
| Next earnings report | Date: 2026-11-04; EPS estimate: $0.814 per share; Revenue estimate: $323.90M The date is our provider's estimate until the company confirms it. | 2026-09-13 | FMP | Financial Modeling Prep (FMP) earnings calendar |
Data provided for informational purposes only.